Literature DB >> 30314999

Phosphoinositides in the kidney.

Leopoldo Staiano1, Maria Antonietta De Matteis1,2.   

Abstract

Phosphoinositides (PIs) play pivotal roles in the regulation of many biological processes. The quality and quantity of PIs is regulated in time and space by the activity of PI kinases and PI phosphatases. The number of PI-metabolizing enzymes exceeds the number of PIs with, in many cases, more than one enzyme controlling the same biochemical step. This would suggest that the PI system has an intrinsic ability to buffer and compensate for the absence of a specific enzymatic activity. However, there are several examples of severe inherited human diseases caused by mutations in one of the PI enzymes, although other enzymes with the same activity are fully functional. The kidney depends strictly on PIs for physiological processes, such as cell polarization, filtration, solute reabsorption, and signal transduction. Indeed, alteration of the PI system in the kidney very often results in pathological conditions, both inherited and acquired. Most of the knowledge of the roles that PIs play in the kidney comes from the study of KO animal models for genes encoding PI enzymes and from the study of human genetic diseases, such as Lowe syndrome/Dent disease 2 and Joubert syndrome, caused by mutations in the genes encoding the PI phosphatases, OCRL and INPP5E, respectively.
Copyright © 2019 Staiano and De Matteis.

Entities:  

Keywords:  Lowe syndrome; genetic diseases; phosphoinositide kinases; phosphoinositide phosphatases

Mesh:

Substances:

Year:  2018        PMID: 30314999      PMCID: PMC6358291          DOI: 10.1194/jlr.R089946

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  122 in total

1.  PTEN-mediated apical segregation of phosphoinositides controls epithelial morphogenesis through Cdc42.

Authors:  Fernando Martin-Belmonte; Ama Gassama; Anirban Datta; Wei Yu; Ursula Rescher; Volker Gerke; Keith Mostov
Journal:  Cell       Date:  2007-01-26       Impact factor: 41.582

Review 2.  Advances in slit diaphragm signaling.

Authors:  Laura A New; Claire E Martin; Nina Jones
Journal:  Curr Opin Nephrol Hypertens       Date:  2014-07       Impact factor: 2.894

3.  WT1-interacting protein and ZO-1 translocate into podocyte nuclei after puromycin aminonucleoside treatment.

Authors:  Maribel Rico; Amitava Mukherjee; Martha Konieczkowski; Leslie A Bruggeman; R Tyler Miller; Shenaz Khan; Jeffrey R Schelling; John R Sedor
Journal:  Am J Physiol Renal Physiol       Date:  2005-03-29

Review 4.  Renal tubule albumin transport.

Authors:  Michael Gekle
Journal:  Annu Rev Physiol       Date:  2005       Impact factor: 19.318

Review 5.  The delivery of endocytosed cargo to lysosomes.

Authors:  J Paul Luzio; Michael D J Parkinson; Sally R Gray; Nicholas A Bright
Journal:  Biochem Soc Trans       Date:  2009-10       Impact factor: 5.407

6.  Lowe oculocerebrorenal syndrome in a female with a balanced X;20 translocation: mapping of the X chromosome breakpoint.

Authors:  O T Mueller; J K Hartsfield; L A Gallardo; Y P Essig; K L Miller; P R Papenhausen; T A Tedesco
Journal:  Am J Hum Genet       Date:  1991-10       Impact factor: 11.025

7.  A molecular switch for the orientation of epithelial cell polarization.

Authors:  David M Bryant; Julie Roignot; Anirban Datta; Arend W Overeem; Minji Kim; Wei Yu; Xiao Peng; Dennis J Eastburn; Andrew J Ewald; Zena Werb; Keith E Mostov
Journal:  Dev Cell       Date:  2014-10-09       Impact factor: 12.270

Review 8.  Inositol polyphosphate phosphatases in human disease.

Authors:  Sandra Hakim; Micka C Bertucci; Sarah E Conduit; David L Vuong; Christina A Mitchell
Journal:  Curr Top Microbiol Immunol       Date:  2012       Impact factor: 4.291

9.  Species-specific difference in expression and splice-site choice in Inpp5b, an inositol polyphosphate 5-phosphatase paralogous to the enzyme deficient in Lowe Syndrome.

Authors:  Susan P Bothwell; Leslie W Farber; Adam Hoagland; Robert L Nussbaum
Journal:  Mamm Genome       Date:  2010-09-26       Impact factor: 2.957

Review 10.  Metastatic renal cell carcinoma.

Authors:  Robert C Flanigan; Steven C Campbell; Joseph I Clark; Maria M Picken
Journal:  Curr Treat Options Oncol       Date:  2003-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.